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Identity 
Other names: MIRN30A 
HGNC (Hugo): MIR30A 
Location: 6q13 
Local order: Based on Mapviewer, genes flanking 
MIR30A oriented from centromere to telomere on 6q13 
are: 
- B3GAT2, beta-1,3-glucuronyltransferase 2 
(glucuronosyltransferase S) 
- MIR30C2, microRNA 30c-2 
- MIR30A, microRNA 30a 
- RIMS1, regulating synaptic membrane exocytosis 1 
- KCNQ5, potassium voltage-gated channel, KQT-like 
subfamily, member 5 
DNA/RNA 
Description 
miR-30 microRNA precursor is a small non-coding 
RNA that regulates gene expression.  
Animal microRNAs are transcribed as ~70 nucleotide 
stem-loop precursor and subsequently processed by the 
Dicer enzyme to give a mature ~22 nucleotide product.  
In this case the mature sequence comes from both  
the 3' (miR-30) and 5' (mir-97-6) arms of the precusor. 
The products are thought to have regulatory roles 
through complementarity to mRNA. A screen of 17 
miRNAs that have been predicted to regulate a number 
of breast cancer associated genes found variations in 
the microRNAs miR-17 and miR-30c-1, these patients 
were noncarriers of BRCA1 or BRCA2 mutations, 
lending the possibility that familial breast cancer may 
be caused by variation in these miRNAs. Members of 
the miR-30 family have been found to be highly 
expressed in heart cells. 
Transcription 
miRNAs are transcribed by RNA polymerase II as part 
of capped and polyadenylated primary transcripts (pri-
miRNAs) that can be either protein-coding or non-
coding. The primary transcript is cleaved by the Drosha 
ribonuclease III enzyme to produce an approximately 
70-nt stem-loop precursor miRNA (pre-miRNA), 
which is further cleaved by the cytoplasmic Dicer 
ribonuclease to generate the mature miRNA. 
Pre-miR Length: 71 bases. 
gcgactgtaa acatcctcga ctggaagctg tgaagccaca gatgggctt  
cagtcggatg tttgcagctg c 
Pseudogene 
No reported pseudogenes. 
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Protein 
Note 
miRNAs are not translated into amino acids. 
Mutations 
Note 




Overexpression of miR-30a suppressed the migration 
and invasiveness phenotypes of breast cancer cell lin s. 
Moreover, reduced tumor expression of miR-30a in 
breast cancer patients was associated with an 
unfavorable outcome, including late tumor stage, 
lymph node metastasis, and worse progression (Cheng 
et al., 2012). 
Prognosis 
Higher expression levels of hsa-miR-30a-3p, hsa-miR
30c, and hsa-miR-182 were significantly associated 
with benefit of tamoxifen treatment and with longer 
PFS (Rodríguez-González et al., 2011). 
Colon carcinoma 
Disease 
miR-30a-5p was shown to be down-regulated in human 
colorectal cancer compared with normal colon mucosa. 
Overexpression of miR-30-5p suppresses proliferation 
colon cancer cell lines by targeting denticleless protein 
homolog (DTL) (Baraniskin et al., 2012). 
Non-small cell lung cancer 
Disease 
microRNA-30a expression was found inversely 
proportional to the invasive potential of various 
NSCLC cell lines, correlating positively with E-
cadherin (epithelial marker) and negatively with N-
cadherin (mesenchymal marker) expression. Lucerfise 
reporter assay indicates snail was a potential targe  of 
miR-30a (Kumarswamy et al., 2012). 
Squamous cell carcinoma 
Note 
Diagnosis: a 5-microRNA classifier (hsa-miR-210, hsa-
miR-182, hsa-miR-486-5p, hsa-miR-30a, and hsa-miR-
140-3p) that could distinguish SCC from normal lung 
tissues (Tan et al., 2011). 
Gastric cancer 
Prognosis 
Li et al identified seven-miRNA signature (miR-10b, 
miR-21, miR-223, miR-338, let-7a, miR-30a-5p, miR-
126) for overall survival (p=0,0009) and relapse-fre 
survival (p=0,0005) of gastric cancer patients (2010). 
Thyroid carcinomas 
Disease 
miR-30a-5p was down-regulated in Thyroid 




miR-30a in regulating beclin 1 expression and 
autophagy reveals a novel function for miRNA in a 
critical cellular event with significant impacts in cancer 
development, progression and treatment (Zhu et al., 
2009). 
miR-30a can sensitize tumor cells to cis-DDP via 
reducing beclin 1-mediated autophagy and that 
increasing miR-30a level in tumor cells represents a 
novel approach to enhance the efficacy of 
chemotherapy during cancer treatment (Zou et al., 
2012). 
Imatinib markedly inhibits expression of miR-30a in 
human CML cells. miR-30a is a potent inhibitor of 
autophagy by downregulating Beclin 1 and ATG5 
expression. miR-30a mimic or knockdown of 
autophagy genes (ATGs) such as Beclin 1 and ATG5 
by short hairpin RNA enhances imatinib-induced 
cytotoxicity and promotes mitochondria-dependent 
intrinsic apoptosis.  
In contrast, knockdown of miR-30a by antagomir-30a 
increases the expression of Beclin 1 and ATG5, and 
inhibits imatinib-induced cytotoxicity (Yu et al., 2012) 
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